Company Overview and News
SAN MIGUEL Food and Beverage, Inc. (SMFBI) — previously known as San Miguel Pure Foods Co., Inc. — is expected to generate P33 billion in earnings this year, once the beer, food, and liquor businesses are fully consolidated under its portfolio, according to sources.
San Miguel Corp. grew its first quarter recurring net income by 31 percent to P19.4 billion.
SAN MIGUEL CORP. (SMC) grew its consolidated recurring profit by a third in the first quarter of 2018, fueled by the performance of its liquor, beer, food, packaging, and fuel businesses.
San Miguel (OTCPK:SMGBY) produced full year results which were very well received by the market. Growth across all its sectors looks set to continue in 2018. It remains a good play on the growing Philippines economy as a whole. In addition there is the possibility of new developments which would cause its stock price to rise faster than the current organic growth and good valuation would imply.
What is set to become the largest share sale in Philippine history may become even bigger after San Miguel Corp.’s chief said he could offer as much as a third of the conglomerate’s soon-to-be-consolidated food and beverage businesses to the investing public.
SAN MIGUEL Pure Foods Company, Inc. (SMPFC) said it has secured the Securities and Exchange Commission (SEC)’s approval to amend its name and primary purpose, among others, to reflect the consolidation of the San Miguel group’s traditional businesses.
San Miguel Pure Foods Company, Inc. (SMPF) said it has secured the Securities and Exchange Commission (SEC)’s approval to amend its name and primary purpose, among others, to reflect the consolidation of the San Miguel group’s traditional businesses.
LOCAL DEBT watcher Philippine Rating Services Corp. (PhilRatings) maintained the top credit rating for San Miguel Brewery, Inc. (SMBI)’s P34.81-billion bonds, citing its continued positive performance and strong position in the market.
SAN MIGUEL Pure Foods Company, Inc. (SMPFC) is pushing back a planned follow-on offering (FOO) to the second half of the year.
SAN MIGUEL Corp. (SMC) chalked up a double-digit growth in recurring earnings last year on the back of the strong performance of its traditional businesses coupled with the positive results of its power and oil segments.
SAN MIGUEL Pure Foods Company, Inc. (SMPFC) booked a double-digit increase in earnings in 2017, boosted by the strong performance of its poultry, fresh meats, and branded business segments.
BARRING any jarring global development, investors in Philippine stocks will likely have their eyes glued to more corporate earnings data that will be released this week, analysts said over the weekend.
SAN MIGUEL Pure Foods Company, Inc. (SMPF) is on track to complete a new manufacturing facility that will produce ready-to-eat products in Laguna by the first quarter of 2019.
SAN MIGUEL Food and Beverage, Inc. (SMFBI) looks to conduct a follow-on offering by the second quarter of 2018 in order to meet the minimum public float of 15%.
AS IN fashion, food also follows trends that mirror what society at present wants (but says they need). San Miguel Pure Foods played trend forecaster this year when the company showcased food trends that it predicts will sizzle this year.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...